Table 1. Crystallographic screening for Slm1-PH domain ligands.

Surrogate ligands	Result	Lipid
Apo Slm1-PH	1.76 Å resolution	Holo form
Ins(4)P	1.4 Å resolution; Ins(4)P bound	PtdIns(4)P
Ins(4)P	1.8 Å resolution; Ins(4)P bound	PtdIns(4)P
PS+Ins(1,4,5)P3	1.68 Å resolution; Phosphoserine bound	DHS-P + PtdIns(4,5)P2
PS+Ins(4)P	2.7 Å resolution; Phosphoserine bound	DHS-1P + PtdIns(4)P
FTY720(P)+Ins(4,5)P2	1.6 Å resolution; No bound ligand	DHS-1P + PtdIns(4,5)P2
Ins(3)P	1.7 Å resolution; No bound ligand	PtdIns(3)P
PS+Ins (3)P	1.6–1.8 Å resolution; No bound ligand	DHS-1P + PtdIns(3)P
PS+Ins(4,5)P2	2.0 Å resolution; No bound ligand	DHS-1P + PtdIns(4,5)P2
PS+Ins(1,4,5)P3	2.5 Å resolution; No bound ligand	DHS-1P + PtdIns(4,5)P2
Ins(1,4,5)P3	2.5 Å resolution; but only in one direction	PtdIns(4,5)P2
Ins(1,4,5)P3	2.6 Å resolution; No bound ligand	PtdIns(4,5)P2
PS+Ins(1,4,5)P3	3.1 Å resolution; No bound ligand	DHS-1P + PtdIns(4,5)P2
Ins(4,5)P2	3.4 Å resolution; No bound ligand	PtdIns(4,5)P2
PS+Ins(1,4,5)P3	4.5 Å resolution; No bound ligand	DHS-1P + PtdIns(4,5)P2
FTY720	Too mosaic diffraction to process so far	DHS
Ins(4)P+Ins(1,4,5)P3	No diffraction	PtdIns(4)P+ PtdIns(4,5)P2
FTY720(P)+Ins(4)P	No crystals	DHS-1P + PtdIns(4)P

^*PS  =  phosphoserine.

^*Crystals of the same protein-ligand complex were obtained in different crystallization conditions.

^*FTY720  =  synthetic analog of sphingosine, currently studied as a potent immunosuppressive and immunomodulatory agent [22], [23], [24]; FTY720(P)  =  phophorylated FTY720.